Enterprise Value
29.85B
Cash
587.6M
Avg Qtr Burn
N/A
Short % of Float
2.02%
Insider Ownership
0.28%
Institutional Own.
79.19%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TYRVAYA (OC-01) (Varenicline) Details Dry eye disease | Approved Quarterly sales | |
OC-01 (Varenicline) Details Neurotrophic Keratopathy | Phase 2 Data readout |